Personal Injury Lawyers
855.800.0093

Testosterone Therapy Lawyers in NJ

The Food and Drug Administration recently issued an alert related to FDA-approved testosterone products, including AndroGel and Testim.  This alert advised the public that the FDA will be looking into the risk of stroke, heart attack and death in men taking these testosterone boosting products. The FDA’s decision to look into the potential risks associated with these products comes after the publication of two different studies that found an increased risk of cardiovascular events in men being treated with some form of testosterone therapy, leading to the contact of our lawyers in NJ.

Testosterone is a hormone that is crucial to male growth, male development and masculine characteristics. As men age, their testosterone levels naturally decline. Testosterone therapy is used to combat this decline by increasing testosterone levels. Testosterone therapy, also known as “low T therapy”, helps to increase testosterone levels, increase muscle mass and bone density, reduce body fat and improve sex drive.

Both of the aforementioned studies found links between prescription testosterone use and an increased risk of heart attack, stroke and death. The Journal of the American Medical Association  (JAMA) published an observational study in November 2013.  The JAMA study relied upon data related to older men in the U.S. Veteran Affairs health system. All of the study’s participants had low serum testosterone and were undergoing imaging of blood vessels of the heart to assess coronary artery disease. The results from this study showed that members of the group who had undergone testosterone therapy had a 30 percent greater risk of stroke, heart attack, and death than those who were not treated with testosterone therapy and could contact testosterone therapy lawyers in NJ.

In January 2014, a second observational study was published by PLOS ONE. This study was done on men 65 years old and older. This second study found that participants receiving testosterone therapy were twice as likely to have a heart attack in the 90 days immediately following the commencement of their testosterone therapy, which was valuable insight for our testosterone therapy lawyers.  The study also found that men under the age of 65 with a pre-existing heart disease were two to three times more likely to have a heart attack in the first 90 days of testosterone therapy.